Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1300 of 2026 entries
View as:

A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02999672 Org: User:
Start: 12/23/16 End: 04/10/18 Due: 04/10/19

A Phase 1 Study of RO6806127 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02196636 Org: User:
Start: 07/31/14 End: 01/31/15 Due: 01/31/16

Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study

Phase: N/A Priority: Normal
NCT ID: NCT01130480 Org: User:
Start: 05/31/10 End: 03/31/12 Due: 03/31/13

Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513

Phase: N/A Priority: Normal
NCT ID: NCT03507569 Org: User:
Start: 04/24/18 End: 06/22/18 Due: 06/22/19

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01376804 Org: User:
Start: 07/31/11 End: 05/31/13 Due: 05/31/14

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00002374 Org: User:
Start: - End: - Due: -

VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT00431353 Org: User:
Start: 04/30/04 End: 08/31/08 Due: 08/31/09

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Phase: N/A Priority: Normal
NCT ID: NCT04404140 Org: User:
Start: 07/09/20 End: 10/14/22 Due: 10/14/23

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Phase: N/A Priority: Normal
NCT ID: NCT02028884 Org: User:
Start: 02/20/14 End: 12/23/21 Due: 12/23/22

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

Phase: N/A Priority: Normal
NCT ID: NCT01235585 Org: User:
Start: 12/31/10 End: 09/30/14 Due: 09/30/15

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01051011 Org: User:
Start: 01/31/10 End: 12/31/10 Due: 12/31/11

A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis

Phase: N/A Priority: Normal
NCT ID: NCT01290094 Org: User:
Start: 04/30/11 End: 07/31/14 Due: 07/31/15

A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT02100696 Org: User:
Start: 05/21/14 End: 04/16/20 Due: 04/16/21

A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT01750957 Org: User:
Start: 02/28/13 End: 04/30/14 Due: 04/30/15

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

Phase: N/A Priority: Normal
NCT ID: NCT02403323 Org: User:
Start: 06/08/15 End: 10/09/23 Due: 10/09/24

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

Phase: N/A Priority: Normal
NCT ID: NCT02913456 Org: User:
Start: 11/16/16 End: 01/31/24 Due: 01/31/25

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03178851 Org: User:
Start: 06/20/17 End: 09/21/20 Due: 09/21/21

An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia

Phase: N/A Priority: Normal
NCT ID: NCT01105494 Org: User:
Start: 12/31/08 End: 06/30/12 Due: 06/30/13

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Phase: N/A Priority: Normal
NCT ID: NCT02624986 Org: User:
Start: 12/23/15 End: 05/20/19 Due: 05/20/20

A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01214733 Org: User:
Start: 10/31/10 End: 05/31/11 Due: 05/31/12

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Phase: N/A Priority: Normal
NCT ID: NCT01287741 Org: User:
Start: 07/26/11 End: 01/31/18 Due: 01/31/19

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01001299 Org: User:
Start: 11/30/09 End: 02/29/12 Due: 02/28/13

An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01071798 Org: User:
Start: 01/31/10 End: 10/31/14 Due: 10/31/15

A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01392755 Org: User:
Start: 07/31/11 End: 09/30/11 Due: 09/30/12

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Phase: N/A Priority: Normal
NCT ID: NCT02828930 Org: User:
Start: 09/08/16 End: 06/19/17 Due: 06/19/18